Deepak Nitrite Profit Triples on Phenolics Surge

CA Aaditya Jain

Oct 30

5 min read

Updated: 14 minutes ago

Cover image of the Katrela Ventures Daily Update for 30 October 2026: Deepak Nitrite Profit Triples on Phenolics Surge

Katrela Ventures Daily Update · Investment, M&A and Business Innovation Digest · 30 October 2026

Key takeaways

Deepak Nitrite's Q2 FY27 revenue rose 61% to ₹3,091 crore, EBITDA 187% to ₹643 crore (20.8% margin) and profit after tax 235% to ₹398 crore.
KIMS Hospitals agreed to acquire 51% of Sarvottam Health Care, operator of a 183-bed Kakinada hospital, for up to ₹80 crore.
NTPC signed a 25-year PPA with an ACME Solar subsidiary for 400 MW of firm renewable power at ₹4.37 per unit.
Funding: Ace Blend raised $9.9 million, Let's Game Now ₹30 crore and Zorit ₹27 crore.

Stay ahead with the latest funding rounds, strategic acquisitions, and groundbreaking innovations shaping the business world!

📩 #Read the full update below.

01. TOP STORIES

KIMS Seals 51% Stake in Kakinada Hospital Operator: Krishna Institute of Medical Sciences (KIMS Hospitals) has executed definitive agreements and remitted consideration of up to ₹80 crore in cash for a 51% stake in Sarvottam Health Care, which runs the 183-bed Trust Multi Speciality Hospital in Kakinada, according to its 29 October filing. The target reported FY26 turnover of ₹84.8 crore and profit after tax of ₹7.1 crore, and the share transfer is pending.

NTPC Locks In 400 MW of Firm Renewable Power From ACME Solar:NTPC has signed a 25-year power purchase agreement with ACME Marigold Urja, a wholly owned subsidiary of ACME Solar Holdings, for 400 MW of firm and dispatchable renewable energy at ₹4.37 per unit, it said on 29 October. Supply under NTPC's FDRE Tranche 01 is scheduled to begin by 30 June 2028.

02. QUICK TAKES

Deepak Nitrite Profit Triples on Phenolics Surge

Deepak Nitrite reported its highest-ever second-quarter performance on 29 October, with consolidated revenue of ₹3,091 crore in Q2 FY27, up 61% year on year. EBITDA rose 187% to ₹643 crore, lifting the EBITDA margin to 20.8%, while profit after tax climbed 235% to ₹398 crore. The company credited agile procurement and deep integration across its facilities for the result in what it described as a challenging operating environment. For the first half, revenue rose 48% to ₹5,682 crore and profit after tax reached ₹743 crore.

The Phenolics segment drove most of the gain, with revenue up 72% to ₹2,291 crore and EBIT up 256% to ₹515 crore, its best quarter on record. Phenolics EBIT for the first half, at ₹933 crore, has already exceeded the segment's previous full-year peak of ₹867 crore set in FY22. Advanced Intermediates grew revenue 38%, supported by steady demand and new products. Management expects upcoming projects to deepen integration and add to revenue and profitability, though it gave no specific targets.

The global backdrop is subdued. The American Chemistry Council's June 2026 outlook projects world chemical output growth of just 0.5% in 2026, rising to 3.2% in 2027, with Asia-Pacific at 1.9% and Europe contracting 1.9% this year. India's picture is stronger: a BCG report published in January 2026 sizes the domestic chemical market at about $150 billion and expects it to surpass $300 billion by 2030. BCG ties that outlook to rising household consumption, a capex cycle and new demand from semiconductor fabrication.

The tailwinds come from domestic demand, which BCG links to beauty and personal care, construction materials and coatings, and from semiconductor fabs that use more than 40 ultra-pure chemicals, most of them imported today. Integrated producers also gain when they can source inputs flexibly, as Deepak's own commentary on procurement suggests. The headwinds are global: SRF flagged volatile global pricing, overcapacity in China and geopolitical developments as pressures on its specialty chemicals business in the same quarter. With world output growth forecast below 1% for 2026, export-led volume gains will be harder to secure.

Peers reporting the same quarter show how uneven the cycle is. SRF grew consolidated revenue 34.7% to ₹4,904 crore and profit after tax 31.2% to ₹509.1 crore, with chemicals segment revenue up 25% to ₹2,079 crore, so Deepak grew faster on both lines (61% revenue, 235% profit). Atul grew revenue 21% to ₹1,877 crore, but its profit after tax fell 13% to ₹158.7 crore and operating profit declined 7.8% to ₹246.6 crore. SRF reported EBIT rather than EBITDA, so a like-for-like comparison with Deepak's 20.8% EBITDA margin is not available. On net profit margin, Deepak's 12.9% compares with about 10.4% for SRF and 8.5% for Atul.

Katrela's Take

➢Deepak Nitrite's quarter shows how backward integration and procurement flexibility can turn a soft global cycle into margin expansion for an Indian producer. For founders and MSMEs supplying the chemical value chain, the clearer opportunity lies in import substitution, especially ultra-pure inputs for semiconductors and specialty intermediates. The constraint is pricing pressure from Chinese overcapacity, which can compress spreads quickly when global demand stays weak. Investors and operators should track Phenolics EBIT, group EBITDA margin, the commissioning of upcoming projects and peer margins next quarter.

Can India's integrated chemical makers sustain margins if Chinese overcapacity persists into 2027?

03. FUNDING BRIEF

Ace Blend-a Bengaluru nutrition and supplements brand-has raised $9.9 million (₹94.4 crore approx.) in a Series A2 round led by 3one4 Capital.

Let's Game Now-a Bengaluru esports and gaming company-has raised ₹30 crore ($3.1 million approx.) in a funding round backed by industrialist Anand Mahindra, Bestvantage Investments and a UAE-based family office.

Zorit-a B2B quick commerce platform for offline retailers, formerly Bijnis-has raised ₹27 crore ($2.8 million approx.) in a round led by Sparrow Capital, with participation from Info Edge, WaterBridge Ventures, Better Capital and angel investors.

Weighing a capital raise or acquisition in specialty chemicals or healthcare? Katrela Ventures can help you structure the next step.

Follow Aaditya Jain , Pradeep Jain and Katrela Ventures for expert insights on investment trends, M&A activities, and business strategy! 💡

Frequently asked questions

How did Deepak Nitrite perform in Q2 FY27?

Consolidated revenue rose 61% to ₹3,091 crore, EBITDA climbed 187% to ₹643 crore with a 20.8% margin, and profit after tax rose 235% to ₹398 crore, its highest-ever second quarter.

What drove Deepak Nitrite's margin expansion?

The company credited agile procurement and deep integration across its facilities, with the phenolics business the main contributor.

What is the opportunity for MSMEs in India's chemical value chain?

Katrela Ventures sees import substitution, especially ultra-pure inputs for semiconductors and specialty intermediates. The constraint is pricing pressure from Chinese overcapacity.

This edition was first published in the Katrela Ventures Daily Update newsletter on LinkedIn. Subscribe to get the digest every morning.

Subscribe on LinkedIn